Perphenazine exerts antitumor effects on HUT78 cells through Akt dephosphorylation by protein phosphatase 2A

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Sezary syndrome is a rare non-Hodgkin lymphoma.
• Protein phosphatase 2A (PP2A) is a tumor suppressor often inhibited in cancers.
• Reactivating PP2A is a promising cancer therapy strategy.

Purpose of the Study:

• Investigate the molecular mechanisms of perphenazine (PPZ) in NRAS-mutated Sezary syndrome cells (HUT78).
• Determine PPZ's effect on Akt and ERK1/2 signaling pathways.
• Evaluate PP2A's role in PPZ's anti-cancer effects.

Main Methods:

• Utilized the HUT78 Sezary syndrome cell line.
• Administered perphenazine (PPZ) and a PP2A inhibitor.
• Assessed Akt and ERK1/2 phosphorylation levels.
• Performed pharmacological inhibition of Akt and ERK1/2 signaling.

Main Results:

• PPZ induced dephosphorylation of Akt and ERK1/2, triggering apoptosis in HUT78 cells.
• A PP2A inhibitor blocked PPZ-mediated Akt dephosphorylation but not ERK1/2 dephosphorylation.
• Akt signaling is crucial for HUT78 cell survival.

Conclusions:

• PPZ exerts antitumor effects in Sezary syndrome by reactivating PP2A.
• PPZ-induced Akt suppression via PP2A activation is a potential therapeutic strategy.
• Targeting Akt signaling may be effective for NRAS-mutated Sezary syndrome.